4 years ago

Iksuda Therapeutics Raises £34 Million to Advance Cancer Therapies

  • Iksuda Therapeutics, a Newcastle-based biotech company, has secured £34 million in funding co-led by Mirae Asset Capital and Celltrion

  • The investment will support the progression of IKS03, a CD19-targeted ADC candidate for B-cell cancers, to a Phase 1 clinical trial

  • The funding will also accelerate the development of IKS04 and IKS012 towards IND filing

  • Iksuda focuses on developing next-generation ADCs targeting difficult-to-treat haematological and solid tumours, utilizing their proprietary PermaLink platform to improve the therapeutic index of this modality

  • The investment reflects the potential of Iksuda's technologies and the expertise of its team.

      • ProblemHealthcare

      "Treating haematological and solid tumours effectively remains a significant challenge in oncology."

      Solution

      "Iksuda Therapeutics develops next-generation antibody-drug conjugates (ADCs) that target these difficult-to-treat tumours with improved efficacy and safety profiles."

      Covered on